Clinical promise of next-generation complement therapeutics

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Nature reviews. Drug discovery

• Publication date

  2019-07-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/s41573-019-0031-6PMID 31324874PMCID PMC7340853
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Consensus report

  2020cited by this paper
• Small-molecule factor B inhibitor for the treatment of complement-mediated diseases

  2019cited by this paper
• Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.

  2019cited by this paper
• Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment.

  2019cited by this paper
• P-selectin drives complement attack on endothelium during intravascular hemolysis in TLR-4/heme-dependent manner

  2019cited by this paper
• New insights into the immune functions of complement

  2019cited by this paper
• Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule

  2019cited by this paper
• Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity

  2019cited by this paper
• Glomerular membrane attack complex is not a reliable marker of ongoing C5 activation in lupus nephritis

  2019cited by this paper
• Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.

  2019cited by this paper
• Toward unrestricted use of public genomic data

  2019cited by this paper
• C3 glomerulopathy — understanding a rare complement-driven renal disease

  2019cited by this paper
• Endothelium structure and function in kidney health and disease

  2019cited by this paper
• Taming hemodialysis-induced inflammation: Are complement C3 inhibitors a viable option?

  2019cited by this paper
• Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles.

  2018cited by this paper
• The multifaceted role of complement in kidney transplantation

  2018cited by this paper
• The oral microbiota: dynamic communities and host interactions

  2018cited by this paper
• The renaissance of complement therapeutics

  2018cited by this paper
• CRISPR/Cas9 generated human CD46, CD55 and CD59 knockout cell lines as a tool for complement research.

  2018cited by this paper
• HLA in transplantation

  2018cited by this paper
• Contribution of alternative complement pathway to delayed hemolytic transfusion reaction in sickle cell disease

  2018cited by this paper
• Janus face of complement-driven neutrophil activation during sepsis.

  2018cited by this paper
• Orthosteric and allosteric action of the C5a receptor antagonists

  2018cited by this paper
• Genetic Analysis of 400 Patients Refines Understanding and Implicates a New Gene in Atypical Hemolytic Uremic Syndrome.

  2018cited by this paper
• Antibody-Mediated Rejection of Solid-Organ Allografts.

  2018cited by this paper
• Protective Effects of the Complement Inhibitor Compstatin CP40 in Hemorrhagic Shock

  2018cited by this paper
• Collectin-11 (CL-11) Is a Major Sentinel at Epithelial Surfaces and Key Pattern Recognition Molecule in Complement-Mediated Ischaemic Injury

  2018cited by this paper
• Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria

  2018cited by this paper
• New Analogs of the Complement C3 Inhibitor Compstatin with Increased Solubility and Improved Pharmacokinetic Profile.

  2018cited by this paper
• Developments in anti‐complement therapy; from disease to clinical trial

  2018cited by this paper
• Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.

  2018cited by this paper
• Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies.

  2018cited by this paper
• Stroke: Opening the therapeutic window

  2018cited by this paper
• Beyond Host Defense: Emerging Functions of the Immune System in Regulating Complex Tissue Physiology.

  2018cited by this paper
• The Complement System in Dialysis: A Forgotten Story?

  2018cited by this paper
• Safety profile after prolonged C3 inhibition.

  2018cited by this paper
• Constrained peptides' time to shine?

  2018cited by this paper
• Structures of C1-IgG1 provide insights into how danger pattern recognition activates complement

  2018cited by this paper
• Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials

  2018cited by this paper
• Complement in Pathophysiology and Treatment of Transplant-Associated Thrombotic Microangiopathies.

  2018cited by this paper
• Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy.

  2018cited by this paper
• Intradialytic Complement Activation Precedes the Development of Cardiovascular Events in Hemodialysis Patients

  2018cited by this paper
• Age and Sex-Associated Changes of Complement Activity and Complement Levels in a Healthy Caucasian Population

  2018cited by this paper
• Outrageous prices of orphan drugs: a call for collaboration.

  2018cited by this paper
• Classical and alternative complement activation on photoreceptor outer segments drives monocyte-dependent retinal atrophy

  2018cited by this paper
• Targeted complement inhibition salvages stressed neurons and inhibits neuroinflammation after stroke in mice

  2018cited by this paper
• Germline mutations in the alternative pathway of complement predispose to HELLP syndrome.

  2018cited by this paper
• Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies.

  2018cited by this paper
• Complement: The Emerging Architect of the Developing Brain.

  2018cited by this paper
• Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation

  2017cited by this paper
• Pharmacological inhibition of complement C5a‐C5a1 receptor signalling ameliorates disease pathology in the hSOD1G93A mouse model of amyotrophic lateral sclerosis

  2017cited by this paper
• Coversin, a Novel C5 Complement Inhibitor, Is Safe and Effective in the Treatment of PNH: Results of a Phase II Clinical Trial

  2017cited by this paper
• Complement in cancer: untangling an intricate relationship

  2017cited by this paper
• Structure and activation of C1, the complex initiating the classical pathway of the complement cascade

  2017cited by this paper
• Pharmacologic Complement Inhibition in Clinical Transplantation

  2017cited by this paper
• Inhibition of complement C5 protects against organ failure and reduces mortality in a baboon model of Escherichia coli sepsis

  2017cited by this paper
• The link between morphology and complement in ocular disease

  2017cited by this paper
• Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases

  2017cited by this paper
• Complement anaphylatoxins C3a and C5a: Emerging roles in cancer progression and treatment.

  2017cited by this paper
• A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome.

  2017cited by this paper
• Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice

  2017cited by this paper
• Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment.

  2017cited by this paper
• Genetics of Immune-Mediated Glomerular Diseases: Focus on Complement.

  2017cited by this paper
• Blocking C5aR signaling promotes the anti-tumor efficacy of PD-1/PD-L1 blockade

  2017cited by this paper
• In vitro evidence of complement activation in transplantation-associated thrombotic microangiopathy.

  2017cited by this paper
• Complement in renal transplantation: The road to translation

  2017cited by this paper
• A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis.

  2017cited by this paper
• Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.

  2017cited by this paper
• A double-blind randomised controlled investigation into the efficacy of Mirococept (APT070) for preventing ischaemia reperfusion injury in the kidney allograft (EMPIRIKAL): study protocol for a randomised controlled trial

  2017cited by this paper
• Novel mechanisms and functions of complement

  2017cited by this paper
• Single-Cell Genomics: Approaches and Utility in Immunology.

  2017cited by this paper
• Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation.

  2017cited by this paper
• Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration

  2017cited by this paper
• Outcomes of hematopoietic cell transplantation using donors or recipients with inherited chromosomally integrated HHV-6.

  2017cited by this paper
• Use of the complement inhibitor Coversin to treat HSCT-associated TMA.

  2017cited by this paper
• Cardiovascular disease in haemodialysis: role of the intravascular innate immune system

  2017cited by this paper
• Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults.

  2017cited by this paper
• Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates

  2017cited by this paper
• Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery.

  2017cited by this paper
• Kallikrein Cleaves C3 and Activates Complement

  2017cited by this paper
• Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.

  2017cited by this paper
• Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia.

  2016cited by this paper
• Protection of host cells by complement regulators

  2016cited by this paper
• Sex matters: Systemic complement activity of female C57BL/6J and BALB/cJ mice is limited by serum terminal pathway components.

  2016cited by this paper
• Injury site‐specific targeting of complement inhibitors for treating stroke

  2016cited by this paper
• Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions

  2016cited by this paper
• Complement in disease: a defence system turning offensive

  2016cited by this paper
• New milestones ahead in complement-targeted therapy.

  2016cited by this paper
• Age-related macular degeneration: Complement in action.

  2016cited by this paper
• Molecular Basis of Assembly and Activation of Complement Component C1 in Complex with Immunoglobulin G1 and Antigen.

  2016cited by this paper
• Mannan binding lectin-associated serine protease-2 (MASP-2) critically contributes to post-ischemic brain injury independent of MASP-1

  2016cited by this paper
• Design and preclinical characterization of ALXN1210: A next generation anti-C5 monoclonal antibody with improved pharmacokinetics and duration of action

  2016cited by this paper
• Complement analysis 2016: Clinical indications, laboratory diagnostics and quality control.

  2016cited by this paper
• Therapeutic control of complement activation at the level of the central component C3.

  2016cited by this paper
• From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage.

  2016cited by this paper
• Collectin-11 detects stress-induced L-fucose pattern to trigger renal epithelial injury.

  2016cited by this paper
• C1 Inhibitor in Acute Antibody‐Mediated Rejection Nonresponsive to Conventional Therapy in Kidney Transplant Recipients: A Pilot Study

  2016cited by this paper
• MASP-3 is the exclusive pro-factor D activator in resting blood: the lectin and the alternative complement pathways are fundamentally linked

  2016cited by this paper
• A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-CC5) Targeting Complement C5 for Treatment of PNH and Complement-Mediated Diseases: Preliminary Phase 1/2 Study Results in Patients with PNH

  2016cited by this paper
• Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome

  2016cited by this paper

• Role of complement in neurologic autoimmunities: Why need to target complement activation for effective immunotherapy.

  2026cites this paper
• Direct choline phosphate Zwitterionization on poly (ether sulfone) offers inhibited coagulation and immune response for blood-contacting ultrafiltration membranes

  2026cites this paper
• Discovery of (3R,4R)-15: An Advanced Factor B Inhibitor Entering Phase 3 for Complement-Mediated Diseases.

  2026cites this paper
• The Complement System in ANCA‐Associated Vasculitis: Mechanistic Insights, Therapeutic Horizons, and Unmet Clinical Needs

  2026influential citation
• Complement and Coagulation Cascades Pathway was Inactivated in HIV-Associated Colorectal Cancer: Results from a Proteomics Study

  2026cites this paper
• Dynamic regulation and targeted intervention of neutrophils in hepatic ischemia‑reperfusion injury (Review).

  2026cites this paper
• Emerging pathological mechanisms of Alzheimer’s disease pathogenesis: from neuroimmune interactions to intercellular communication

  2026cites this paper
• Complement Inhibitors and the Risk of (Breakthrough) Infections—Critical Analysis and Preventive Strategies

  2026cites this paper
• C‐model: A comprehensive enhanced pharmacokinetic/pharmacodynamic simulation environment targeting the complement system

  2025cites this paper
• The state of the hemostasis system in patients suffering from a severe course of the coronavirus infection SARS-CoV-2 COVID-19, during hospitalization (results of a randomized clinical study)

  2025cites this paper
• The complement system: Biology, pathology, and therapeutic interventions.

  2025cites this paper
• Identification and Validation of a Novel Prognostic Signature of Gastric Cancer Based on Seven Complement System-Related Genes: An Integrated Analysis.

  2025cites this paper
• Genetic Determinants of the Complement and Coagulation Pathways in Invasive Meningococcal Disease.

  2025cites this paper
• Red blood cells undergo lytic programmed cell death involving NLRP3.

  2025cites this paper
• Differential effects of C5 inhibition, C3 inhibition, and alternative pathway inhibition on bacterial killing in vitro

  2025cites this paper
• FastCCC: a permutation-free framework for scalable, robust, and reference-based cell-cell communication analysis in single cell transcriptomics studies

  2025cites this paper
• Decrease in Urinary Tract Infections Following Switch From Anti-Interleukin-6 Monoclonal Antibody to Ravulizumab in a Patient With Neuromyelitis Optica Spectrum Disorder (NMOSD): A Case Report

  2025cites this paper
• Cerebrospinal fluid proteomics exerts predictive potential for immune effector cell-associated neurotoxicity syndrome (ICANS) in CAR-T cell therapy

  2025cites this paper
• Clinical Value of Complement C3a, C5a, and sC5b-9 in Evaluating the Severity of Patients with Severe Fever with Thrombocytopenia Syndrome

  2025cites this paper
• Dynamic Complement Protein Changes in Aqueous Humor and Plasma of Patients With Retinal Vein Occlusion During Ranibizumab Treatment

  2025cites this paper
• Blocking activation of the C1r zymogen defines a novel mode of complement inhibition

  2025cites this paper
• Randomized phase I trial outcomes show safe and sustainable inhibition of classical and lectin complement pathways by empasiprubart

  2025cites this paper
• Sepsis-Induced Endothelial Barrier Dysfunction: Mechanisms, Pathology, and Therapeutic Advances

  2025cites this paper
• Management of Myasthenic Crisis and Emerging Roles of Molecularly Targeted Therapies: A Narrative Review

  2025cites this paper
• Targeting Thromboinflammation in Purpura Fulminans: Novel Therapeutic Avenues in Critical Care

  2025cites this paper
• The complement system and kidney cancer: pathogenesis to clinical applications

  2025cites this paper
• Role of Complement Anaphylatoxins (C3a and C5a) in Lymphoma: A Systematic Review

  2025cites this paper
• Enhanced immunocompatibility and hemocompatibility of nanomedicines across multiple species using complement pathway inhibitors

  2025cites this paper
• Complement system: A key player in hepatic ischemia-reperfusion injury.

  2025cites this paper
• Cross-species analysis identifies genotype-driven vulnerabilities in lung adenocarcinoma

  2025cites this paper
• Inflammatory responses revealed through HIV infection of microglia-containing cerebral organoids

  2025cites this paper
• Risk Factor Analysis for Recurrence of Subacute Necrotizing Lymphadenitis in Children

  2025cites this paper
• The life-and-death struggle between the complement system and pathogens: Mechanisms of elimination, evasion tactics, and translational potential

  2025cites this paper
• Emerging molecular targets in deep vein thrombosis: from inflammation to coagulation

  2025cites this paper
• The Complement System.

  2025cites this paper
• Complement regulation in the eye: implications for age-related macular degeneration

  2024cites this paper
• The Inflammatory Response Induced by Aspergillus fumigatus Conidia Is Dependent on Complement Activation: Insight from a Whole Blood Model

  2024cites this paper
• PolySialic Acid Nanoparticles Actuate Complement-Factor-H-Mediated Inhibition of the Alternative Complement Pathway: A Safer Potential Therapy for Age-Related Macular Degeneration

  2024influential citation
• 补体C5/C5a在Graves眼病诊断与治疗中的价值：一项孟德尔随机化研究

  2024cites this paper
• DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease

  2024cites this paper
• Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose riliprubart, an anti-C1s humanized monoclonal antibody in East-Asian adults: results from a Phase 1, randomized, open-label trial

  2024cites this paper
• Integrated Applied Clinical Pharmacology in the Advancement of Rare and Ultra‐Rare Disease Therapeutics

  2024cites this paper
• A selective alternative pathway complement inhibitor for treatment of paroxysmal nocturnal hemoglobinuria

  2024cites this paper
• Design and Biological Evaluation of the Long-Acting C5-Inhibited Ornithodoros moubata Complement Inhibitor (OmCI) Modified with Fatty Acid.

  2024cites this paper
• New treatment strategies in Myasthenia gravis.

  2024cites this paper
• CSF complement proteins are elevated in prodromal to moderate Alzheimer's disease patients and are not altered by the anti‐tau antibody semorinemab

  2024cites this paper
• Preclinical safety and efficacy of the recombinant CR1 drug product CSL040 in rats and cynomolgus monkeys.

  2024cites this paper
• Antibodies and complement are key drivers of thrombosis.

  2024cites this paper
• Recruiting the Immune System against Pathogenic Bacteria Using High-Affinity Chimeric Tags

  2024cites this paper
• The complement system in clinical oncology: Applications, limitations and challenges.

  2024cites this paper
• Immunodeficiency: Complement disorders.

  2024cites this paper
• The Interconnection Between the Liver and Other Organs: Insights for Hepatic Long–Term Normothermic Machine Perfusion

  2024cites this paper
• A Histological Analysis and Detection of Complement Regulatory Protein CD55 in SARS-CoV-2 Infected Lungs

  2024cites this paper
• An optimized protocol for the expression of a recombinant protein fragment of human factor B used for the production of polyclonal antibodies

  2024cites this paper
• Impact of Preanalytical Procedures on Complement Biomarkers in Cerebrospinal Fluid and Plasma from Controls and Alzheimer’s Disease Patients

  2024cites this paper
• Plant derived bioactive compounds for the treatment of neurodegeneration and neuroimmune disorders associated with the complement system

  2024cites this paper
• Progress in Targeted Therapy for Myasthenia Gravis

  2024cites this paper
• Structure-property Relationships Reported for the New Drugs Approved in 2023.

  2024cites this paper
• HIV-1 infection promotes neuroinflammation and neuron pathogenesis in novel microglia-containing cerebral organoids

  2024cites this paper
• Salivary Proteomics for Detecting Novel Biomarkers of Periodontitis: A Systematic Review

  2024cites this paper
• Astrocyte-secreted C3 signaling impairs neuronal development and cognition in autoimmune diseases.

  2024cites this paper
• Balancing efficacy and safety of complement inhibitors.

  2024cites this paper
• Complement C3 knockout protects photoreceptors in the sodium iodate model.

  2024cites this paper
• Complement‐targeted therapeutics: Are we there yet, or just getting started?

  2024cites this paper
• Discovery and Characterization of a New Class of C5aR1 Antagonists Showing In Vivo Activity.

  2024cites this paper
• Complements from the Male Reproductive Tract: A Scoping Review

  2024cites this paper
• Targeting the complement system in geographic atrophy: mechanisms and therapeutics

  2023cites this paper
• Editorial: Current challenges in complement diagnostics

  2023cites this paper
• Complement C3 as a potential drug target in periodontitis: Evidence from the cis-Mendelian randomization approach.

  2023cites this paper
• Inhibition of acute complement responses towards bolus-injected nanoparticles using targeted short-circulating regulatory proteins

  2023cites this paper
• Complement and coagulation cascades pathway-related signature as a predictor of immunotherapy in metastatic urothelial cancer

  2023cites this paper
• The Complement-Targeted Inhibitor Mini-FH Protects against Experimental Periodontitis via Both C3-Dependent and C3-Independent Mechanisms.

  2023cites this paper
• Clinical research advances of CFHR5 nephropathy: a recent review.

  2023cites this paper
• Prognostic Model and Tumor Immune Microenvironment Analysis of Complement-Related Genes in Gastric Cancer

  2023cites this paper
• Targeting synapse function and loss for treatment of neurodegenerative diseases

  2023cites this paper
• Pan-Neurofascin autoimmune nodopathy – a life-threatening, but reversible neuropathy

  2023cites this paper
• Properdin inhibition ameliorates hepatic ischemia/reperfusion injury without interfering with liver regeneration in mice

  2023cites this paper
• A guide to complement biology, pathology and therapeutic opportunity

  2023influential citation
• In vaccinated individuals serum bactericidal activity against B meningococci is abrogated by C5 inhibition but not by inhibition of the alternative complement pathway

  2023influential citation
• C5a-licensed phagocytes drive sterilizing immunity during systemic fungal infection.

  2023cites this paper
• New‐onset and relapsed thrombotic microangiopathy post‐COVID‐19 vaccination

  2023cites this paper
• Revisiting the relationship between complement and ulcerative colitis

  2023cites this paper
• Using human genetics to validate complement C3 as a drug target in periodontitis

  2023influential citation
• The case for complement component 5 as a target in neurodegenerative disease

  2023cites this paper
• MASP3 Deficiency in Mice Reduces but Does Not Abrogate Alternative Pathway Complement Activity Due to Intrinsic Profactor D Activity.

  2023cites this paper
• Microglia PKM2 Mediates Neuroinflammation and Neuron Loss in Mice Epilepsy through the Astrocyte C3-Neuron C3R Signaling Pathway

  2023cites this paper
• Anti-C1s humanized monoclonal antibody SAR445088: A classical pathway complement inhibitor specific for the active form of C1s.

  2023cites this paper
• Quantification of the zymogenicity and the substrate-induced activity enhancement of complement factor D

  2023cites this paper
• Complement: Functions, location and implications

  2023cites this paper
• Complement‐mediated immune mechanisms in allergy

  2023cites this paper
• Reactivating the complement system using peptidic bacterial labeling tag

  2023cites this paper
• Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation

  2023cites this paper
• The role of C5a receptors in autoimmunity.

  2023cites this paper
• The Platelet Anaphylatoxin Receptor C5aR1 (CD88) Is a Promising Target for Modulating Vessel Growth in Response to Ischemia a

  2023cites this paper
• Venous thromboembolism in viral diseases: A comprehensive literature review

  2023cites this paper
• Complement‐targeted therapeutics: An emerging field enabled by academic drug discovery

  2023cites this paper
• Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration

  2023cites this paper
• Alexandar Gerogianni-omslag.indd

  2023cites this paper
• rhMYDGF Alleviates I/R-induced Kidney Injury by Inhibiting Inflammation and Apoptosis via the Akt Pathway

  2023cites this paper
• Immunogenicity and Safety of Anti-SARS-CoV-2 mRNA Vaccines in a Cohort of Patients with Hereditary Angioedema

  2023cites this paper